obixibat水合物是一种胆酸转运体（IBAT）的有效抑制剂，对人类IBAT的IC50值为0.53±0.17 nM，对小鼠IBAT的IC50值为0.13±0.03 nM，对犬IBAT的IC50值为5.8±1.6 nM。Elobixibat水合物可用于老年慢性特发性便秘（CIC）的研究。

GSK2330672 is a highly potent, nonabsorbable ASBT (apical sodium-dependent bile acid transporter) inhibitor (hASBT IC50=42 ± 3 nM) which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes.

Odevixibat (A4250) 是一种有效的选择性顶端钠依赖性胆汁酸转运蛋白 (ASBT) 抑制剂。Odevixibat 在小鼠模型中缓解胆管损伤和胆汁淤积，可用于原发性胆汁性肝硬化的研究。

Elobixibat is a potent ileal bile acid transporter (IBAT) inhibitor with IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT.

S-8921 is an ileal Na+/bile acid cotransporter (IBAT) inhibitor.